药物治疗心衰并慢性肾脏病患者的疗效及安全性.pptx

上传人:wuy****n92 文档编号:80427404 上传时间:2023-03-23 格式:PPTX 页数:16 大小:1.70MB
返回 下载 相关 举报
药物治疗心衰并慢性肾脏病患者的疗效及安全性.pptx_第1页
第1页 / 共16页
药物治疗心衰并慢性肾脏病患者的疗效及安全性.pptx_第2页
第2页 / 共16页
点击查看更多>>
资源描述

《药物治疗心衰并慢性肾脏病患者的疗效及安全性.pptx》由会员分享,可在线阅读,更多相关《药物治疗心衰并慢性肾脏病患者的疗效及安全性.pptx(16页珍藏版)》请在得力文库 - 分享文档赚钱的网站上搜索。

1、LOGO新型盐皮质受体拮抗剂治疗心衰并慢性新型盐皮质受体拮抗剂治疗心衰并慢性新型盐皮质受体拮抗剂治疗心衰并慢性新型盐皮质受体拮抗剂治疗心衰并慢性肾脏病患者的疗效及安全性肾脏病患者的疗效及安全性肾脏病患者的疗效及安全性肾脏病患者的疗效及安全性20132013European Heart Journal(2013)34,24532463LOGOContentsContentsAimMethods and ResultsConclusionAIMAIMvMineralocorticoid receptor antagonists(MRAs)improve outcomes in patients w

2、ith heart failure and reduced left ventricular ejection fraction(HFrEF),but their use is limited by hyperkalaemia and/or worsening renal function(WRF).vBAY 94-8862 is a highly selective and strongly potent non-steroidal MRA.vWe investigated its safety and tolerability in BAY 94-8862 is a highly sele

3、ctive and strongly potent non-steroidal MRA.We investigated its safety and tolerability in patients with HFrEF associated with mild or moderate chronic kidney disease(CKD).LOGOMethods and resultsMethods and resultsvThis randomized,controlled,phase II trial consisted of two parts.vIn part A,the safet

4、y and tolerability of oral BAY 94-88622.5,5,or 10 mg once daily(q.d.)was assessed in 65 patients with HFrEF and mild CKD.vIn part B,BAY 94-8862(2.5,5,or 10 mg q.d.,or 5 mg twice daily)was compared with placebo and open-label spironolactone(25 or 50 mg/day)in 392 patients with HFrEF and moderate CKD.

5、LOGOResultsResultsvBAY 94-8862 was associated with significantly smaller mean increases in serum potassium concentration than spironolactone(0.040.30 and 0.45 mmol/L,respectively,P0.00010.0107)and lower incidences of hyperkalaemia(5.3 and 12.7%,respectively,P=0.048)and WRF.LOGOResultsResultsvBAY 94-

6、8862 decreased the levels of B-type natriuretic peptide(BNP),amino-terminal proBNP,and albuminuria at least as much as spironolactone.vAdverse events related to BAY 94-8862 were infrequent and mostly mild.LOGOConclusionConclusionvIn patients with HFrEF and moderate CKD,BAY 94-8862 510 mg/day was at least as effective as spironolactone 25 or 50 mg/day in decreasing biomarkers of haemodynamic stress,but it was associated with lower incidences of hyperkalaemia and WRF.LOGOLOGOLOGOLOGOLOGOLOGOLOGOLOGOLOGOLOGO

展开阅读全文
相关资源
相关搜索

当前位置:首页 > 教育专区 > 大学资料

本站为文档C TO C交易模式,本站只提供存储空间、用户上传的文档直接被用户下载,本站只是中间服务平台,本站所有文档下载所得的收益归上传人(含作者)所有。本站仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。若文档所含内容侵犯了您的版权或隐私,请立即通知得利文库网,我们立即给予删除!客服QQ:136780468 微信:18945177775 电话:18904686070

工信部备案号:黑ICP备15003705号-8 |  经营许可证:黑B2-20190332号 |   黑公网安备:91230400333293403D

© 2020-2023 www.deliwenku.com 得利文库. All Rights Reserved 黑龙江转换宝科技有限公司 

黑龙江省互联网违法和不良信息举报
举报电话:0468-3380021 邮箱:hgswwxb@163.com